Protalix Biotherapeutics Inc
PLX1.495USD
+0.045+3.10%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
116.81MCap. mercado
29.89P/E TTM
Más Datos de Protalix Biotherapeutics Inc Compañía
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.
Información de la empresa
Símbolo de cotizaciónPLX
Nombre de la empresaProtalix Biotherapeutics Inc
Fecha de salida a bolsaSep 06, 2010
Director ejecutivoMr. Dror Bashan
Número de empleados207
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 06
Dirección2 University Plaza
CiudadHACKENSACK
Bolsa de valoresEuronext Paris
PaísUnited States of America
Código postal07601
Teléfono12016969345
Sitio Webhttps://protalix.com/
Símbolo de cotizaciónPLX
Fecha de salida a bolsaSep 06, 2010
Director ejecutivoMr. Dror Bashan
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.28M
--
Mr. Eyal Rubin
Mr. Eyal Rubin
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
660.91K
+15.95%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
207.30K
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
174.00K
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
40.00
--
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
40.00
--
Mr. Mike Moyer
Mr. Mike Moyer
Investor Relations
Investor Relations
--
--
Mr. Amos Bar Shalev
Mr. Amos Bar Shalev
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Eliot Richard Forster, Ph.D.
Dr. Eliot Richard Forster, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.28M
--
Mr. Eyal Rubin
Mr. Eyal Rubin
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Chief Financial Officer, Senior Vice President, Treasurer, Secretary
660.91K
+15.95%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
207.30K
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
174.00K
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
40.00
--
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
40.00
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 23 de jul
Actualizado: mié., 23 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
HIR Investments Ltd
5.92%
Bashan (Dror)
2.87%
Renaissance Technologies LLC
1.49%
Millennium Management LLC
1.21%
Susquehanna International Group, LLP
1.08%
Other
87.43%
Accionistas
Accionistas
Proporción
HIR Investments Ltd
5.92%
Bashan (Dror)
2.87%
Renaissance Technologies LLC
1.49%
Millennium Management LLC
1.21%
Susquehanna International Group, LLP
1.08%
Other
87.43%
Tipos de accionistas
Accionistas
Proporción
Corporation
6.22%
Investment Advisor
4.67%
Individual Investor
4.18%
Hedge Fund
3.67%
Investment Advisor/Hedge Fund
2.30%
Research Firm
0.82%
Pension Fund
0.26%
Venture Capital
0.05%
Other
77.84%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
182
17.64M
22.16%
+1.73M
2025Q1
182
19.45M
25.30%
+4.26M
2024Q4
169
15.65M
21.26%
-1.03M
2024Q3
162
14.11M
19.17%
-5.41M
2024Q2
163
16.36M
22.25%
-4.44M
2024Q1
143
16.45M
23.43%
-4.40M
2023Q4
145
17.20M
24.67%
-3.21M
2023Q3
142
16.45M
24.08%
-6.46M
2023Q2
132
16.38M
24.76%
-4.13M
2023Q1
95
13.57M
27.32%
-11.07M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
HIR Investments Ltd
4.71M
5.92%
--
--
Apr 30, 2025
Bashan (Dror)
2.28M
2.87%
--
--
Apr 30, 2025
Renaissance Technologies LLC
1.19M
1.49%
+70.95K
+6.35%
Mar 31, 2025
Millennium Management LLC
963.01K
1.21%
+575.09K
+148.25%
Mar 31, 2025
Susquehanna International Group, LLP
858.65K
1.08%
+858.65K
--
Mar 31, 2025
Northern Trust Global Investments Limited
683.30K
0.86%
-46.98K
-6.43%
Mar 31, 2025
Rubin (Eyal)
660.91K
0.83%
+90.91K
+15.95%
Apr 30, 2025
Marshall Wace LLP
615.09K
0.77%
+513.19K
+503.62%
Mar 31, 2025
Connor, Clark & Lunn Investment Management Ltd.
482.88K
0.61%
+482.88K
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
Franklin US Small Cap Multifactor Index ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
Avantis International Small Cap Equity ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Ver más
iShares Micro-Cap ETF
Proporción0.02%
iShares Russell 2000 Growth ETF
Proporción0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporción0.01%
Franklin US Small Cap Multifactor Index ETF
Proporción0.01%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Global X Russell 2000 ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
Avantis International Small Cap Equity ETF
Proporción0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
